All In Biotech

Drug Trial Radar · NCT06987513

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

May 15, 2025

Primary completion

Jul 30, 2026

Study completion Jul 30, 2026

Sponsor

Lead sponsor
Altimmune, Inc.Industry
Sponsor type
Industry
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly

Conditions

  • Alcohol Use Disorder (AUD)

Interventions

  • PemvidutideDrug

    Pemvidutide 2.4 mg SC once weekly

  • PlaceboOther

    Placebo SC once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the average number of heavy drinking days per weekTime frame: Baseline to Weeks 21-24

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Altimmune Clinical Study Site

    Los Angeles, California

  • Altimmune Clinical Study Site

    Aurora, Colorado

  • Altimmune Clinical Study Site

    New Haven, Connecticut

  • Altimmune Clinical Study Site

    Fort Myers, Florida

  • Altimmune Clinical Study Site

    University Park, Florida

  • Altimmune Clinical Study Site

    North Canton, Ohio

  • Altimmune Clinical Study Site

    Tulsa, Oklahoma

  • Altimmune Clinical Study Site

    Philadelphia, Pennsylvania

  • Altimmune Clinical Study Site

    Providence, Rhode Island

  • Altimmune Clinical Study Site

    Charleston, South Carolina

  • Altimmune Clinical Study Site

    Charlottesville, Virginia

  • Altimmune Clinical Study Site

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.